Impact Factor
4.32
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
7.56
2,242 total citations
h5-index
56
h5 depth signal
Cited share
86.1%
260 of 302
Total citations
2,242
Citation footprint
Metric signal
6.12
External metric anchor
Self-citation
18.0%
404 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
988
United Kingdom
200
Germany
126
Canada
96
Israel
93
Citing Fields of Research
Diabetes
1,508
Obstetrics/Gynecology
79
Nutrition & Dietetics
60
Health Education & Remote Healthcare
49
Clinical Laboratory Science
44
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,840
Articles tracked across the journal lifetime
Indexed publication set
302
260 cited publications
Last 12 months
235
19.6 publications/month
Open access share
15.3%
36 OA publications in the last year
Leading citing country
United States
988 citing publications
Leading citing field
Diabetes
1,508 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1n1, spring 1999-
v1n1, spring 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Diabetes
Broad Categories
Endocrinology
Therapeutics
Diabetes
MeSH Descriptors
Blood Glucose Self-Monitoring
Diabetes Mellitus
Equipment and Supplies
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/15209156261496625
Open DOI
Real-World Clinical Outcomes Following Initiation of the iLet® Bionic Pancreas in Youth with Type 1 Diabetes
Background: The iLet ® Bionic Pancreas replaces carbohydrate counting and manual bolus calculations with simplified qualitative meal announcements. Its performance among diverse patients with high baseline glycated hemoglobin (HbA1c) is ...
02
DOI 10.1177/15209156261496632
Open DOI
Efficacy and Safety of the MiniMed™ Vivera™ Algorithm: Results from a First-in-Human Feasibility Trial
MiniMed™ Vivera™ is an automated insulin delivery algorithm designed to make meal announcements optional. This first-in-human feasibility trial evaluated the efficacy and safety of the algorithm under different meal-announcement strategi...
03
DOI 10.1177/15209156261489912
Open DOI
Pediatric Inpatient Continuous Glucose Monitoring: Development and Implementation of a Hospital Policy for Accuracy-Validated Insulin Dosing
Objective: We assessed the safety, clinical accuracy, glycemic outcomes, user outcomes, and implementation of a pediatric hospital-wide continuous glucose monitor (CGM) policy. Research Design and Methods: We used the Model for Improveme...
04
05
DOI 10.1177/15209156261496613
Open DOI
Association of HbA1c with Time in Range, Time in Tight Range, Empirically Derived Continuous Glucose Monitoring Glucose Ranges, and Mean Glucose
Objective: To evaluate how continuous glucose monitoring (CGM) glucose thresholds, sampling duration, and statistical modeling influence associations between CGM-derived range metrics and HbA1c, and to compare empirically derived glucose...
06
DOI 10.1177/15209156261496643
Open DOI
Roadmap to Fully Closing the Loop to Optimize Health in Type 1 Diabetes
Objective: Current commercially available automated insulin delivery systems require meal and exercise announcements for optimal function, placing them in the hybrid closed loop category. Ongoing advancements aim to establish fully close...
07
DOI 10.1177/15209156261493676
Open DOI
Comparison of Blood Glucose Values Used for Impending Non-Severe Hypoglycemia Management with Corresponding Continuous Glucose Monitoring Data in Type 1 Diabetes: A Secondary Analysis of the REVERSIBLE Trial
Background: To assess continuous glucose monitoring (CGM) data corresponding to blood glucose (BG) values used for impending non-severe (NS) hypoglycemia management in people living with type 1 diabetes (PwTID). Methods: We performed a s...
08
DOI 10.1177/15209156261492040
Open DOI
Exploratory Analysis of Continuous Glucose Monitoring Patterns in First-Degree Relatives with Dysglycemia at Risk of Progression to Stage 3 Type 1 Diabetes
Introduction: Continuous glucose monitoring (CGM) can characterize subtle glucose changes in early-stage type 1 diabetes (T1D). We assessed whether CGM metrics predict Stage 3 T1D in first-degree relatives (FDRs) with positive islet auto...
09
DOI 10.1177/15209156261489913
Open DOI
Factors Associated with Utilization and Underutilization of Diabetes Technology in Underrepresented Families Living with Type 1 Diabetes
Continuous glucose monitoring (CGM) and insulin pumps improve glycemic outcomes and quality of life for youth with type 1 diabetes, yet utilization remains suboptimal. We analyzed cross-sectional data from 84 parent-youth dyads in the Bu...
10
DOI 10.1177/15209156261492377
Open DOI
Continuous Glucose Monitoring and Hospitalization Outcomes in Adults with Insulin-Treated Type 2 Diabetes and Complex Care Needs: A Population-Based Study
Aim: Continuous glucose monitoring (CGM) improves glycemic outcomes in insulin-treated type 2 diabetes (T2D), but evidence in individuals with complex care needs (CCN) is limited. We evaluated the association between CGM initiation and h...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
v.1, no. 1 (Mar. 1999)20010712 Notice not published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper